In the adjunct 1 trial,25 adding liraglutide to insulin therapy in 1398 adults with T1D over 52 weeks resulted in significantly reduced HbA1c levels (0.34%-0.54% from an initial 8.2%) and lower insulin doses in the liraglutide 1.8 and 1.2 mg groups.25 Mean body weight significantly decreased across all liraglutide groups compared to placebo: 1.8 mg: −4.9 kg, 1.2 mg: −3.6 kg, and 0.6 mg: −2.2 kg.25 The gene discussed is INS; the disease is type 1 diabetes mellitus.